Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
801
mi
from 43215
Baton Rouge, LA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
801
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
845
mi
from 43215
Lafayette, LA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
845
mi
from 43215
Lafayette, LA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
155
mi
from 43215
Southgate, MI
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
155
mi
from 43215
Southgate, MI
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
537
mi
from 43215
Columbus, MS
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
537
mi
from 43215
Columbus, MS
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
745
mi
from 43215
Gulfport, MS
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
745
mi
from 43215
Gulfport, MS
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
417
mi
from 43215
Sewell, NJ
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
417
mi
from 43215
Sewell, NJ
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
492
mi
from 43215
Great Neck, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
492
mi
from 43215
Great Neck, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
496
mi
from 43215
Mineola, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
496
mi
from 43215
Mineola, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
482
mi
from 43215
Ridgewood, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
482
mi
from 43215
Ridgewood, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
491
mi
from 43215
Rosedale, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
491
mi
from 43215
Rosedale, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
484
mi
from 43215
Wilmington, NC
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
484
mi
from 43215
Wilmington, NC
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
316
mi
from 43215
Fairfax, VA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
316
mi
from 43215
Fairfax, VA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
423
mi
from 43215
Portsmouth, VA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
423
mi
from 43215
Portsmouth, VA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
394
mi
from 43215
Madison, WI
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
394
mi
from 43215
Madison, WI
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
4380
mi
from 43215
Feldkirch,
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
4380
mi
from 43215
Feldkirch,
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northern California
2098
mi
from 43215
Oakland, CA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northern California
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of California
2109
mi
from 43215
San Francisco, CA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of California
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Illinois at Chicago
274
mi
from 43215
Chicago, IL
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Illinois at Chicago
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Tulane University Health Sciences Center
797
mi
from 43215
New Orleans, LA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Tulane University Health Sciences Center
797
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medical Institutions
345
mi
from 43215
Baltimore, MD
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medical Institutions
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Maryland Medical System
343
mi
from 43215
Baltimore, MD
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Maryland Medical System
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospitals
164
mi
from 43215
Ann Arbor, MI
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospitals
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
St. John Hospital and Medical Center/RRRI
163
mi
from 43215
Detroit, MI
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
St. John Hospital and Medical Center/RRRI
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Wayne State - Harper University Hospital
164
mi
from 43215
Detroit, MI
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Wayne State - Harper University Hospital
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
127
mi
from 43215
Cleveland, OH
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland
129
mi
from 43215
Cleveland, OH
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
The University of Pennsylvania Medical Center
416
mi
from 43215
Philadelphia, PA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
The University of Pennsylvania Medical Center
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1970
mi
from 43215
Glendale, AZ
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 43215
Glendale, AZ
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1639
mi
from 43215
Tucson, AZ
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1952
mi
from 43215
Azusa, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1952
mi
from 43215
Azusa, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1949
mi
from 43215
Chula Vista, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1949
mi
from 43215
Chula Vista, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1969
mi
from 43215
Downey, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1969
mi
from 43215
Downey, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1865
mi
from 43215
El Centro, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1865
mi
from 43215
El Centro, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1942
mi
from 43215
La Mesa, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1942
mi
from 43215
La Mesa, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1975
mi
from 43215
Long Beach, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1975
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1935
mi
from 43215
Riverside, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1935
mi
from 43215
Riverside, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2039
mi
from 43215
Sacramento, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2039
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1167
mi
from 43215
Arvada, CO
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1167
mi
from 43215
Arvada, CO
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1163
mi
from 43215
Westminster, CO
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1163
mi
from 43215
Westminster, CO
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
968
mi
from 43215
Lauderdale Lakes, FL
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
968
mi
from 43215
Lauderdale Lakes, FL
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
897
mi
from 43215
Port Charlotte, FL
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
897
mi
from 43215
Port Charlotte, FL
Click here to add this to my saved trials